1. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997 Jan;4(1):57-63.)
2. Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS;Chai XS; et al, Efficacy of tablet huperzine-A on memory’ cognition’ and behavior. Chung Kuo Yao Li, Hsueh Pao16:391-5, 1995.)
3. Santos MS, Duarte AI, Moreira PI, Oliveira CR Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res 2000 Jan;32(1):57-66
4. Dean W, Morgenthaler J. Smart Drugs & Nutrients.
5. Kostopoulos GK, Phillis JW. The effects of dimethylaminoethanol (deanol) on cerebral cortical neurons. Psychopharmacol Commun. 1975; 1(3):339-47.
6. Levin ED, Rose JE, Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance. Pharmacol Biochem Behav. 1995; 51(2-3):369-73.
7. Flood JF, Smith GE, Cherkin A. Memory retention: potentiation of cholinergic drug combinations. Neurobiol Aging. 1983; 4(1):37-43.
8. Nagy I, Nagy K. On the role of cross-linking of cellular proteins in aging. Mech Ageing Dev. 1980;14(1-2):245-51.
9. Marsh GR, Linnoila M. The effects of deanol on cognitive performance and electrophysiology in elderly humans. Psychopharmacology (Berl). 1979; 66(1):99-104.
10. Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer’s disease. Am J Psychiatry. 1981; 138(7):970-2.
11. Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Clin Pharmacol Ther. 1975; 17(5):534-40.
12. Pfeiffer C. Nutrition and Mental Illness: An Orthomolecular Approach to Balancing Body Chemistry. Healing Arts Press.
13. Cenni, A., et al. “Pharmacological Properties of a Nootropic Agent of Endogenous Origin: D-Pyroglutamic Acid.” Journal of Drug Development. 1988, 1, pp. 157-62.
14. Drago, F., Continella, G., Valerio, C., D’Agata, V., Astuto, C., Spardaro, F., Scapagnini, U. “Effects of Pyroglutamic Acid on Learning and Memory Processes.” Acta Therapeutica. 1987, Vol. 13, pp. 587-94.
15. Filippo, V., Spignoli, G., Isidori, A. “Effects of Arginine Pyroglutamate on Growth Hormone in Children.” Clinical Trials Journal. 1987, Vol. 24, pp. 387-90.
16. Grioli, S. et al. “Pyroglutamic Acid Improves the Age Associated Memory Impairment.” Fundamental and Clinical Pharmacology. 1990, Vol. 4, pp. 169-73.
17. Moret, C., Briley, M. “The Forgotten Amino Acid Pyroglutamate.” Trends in Pharmacological Sciences. 1988, Vol. 9, pp. 278-9.
18. Paoli, F., Spignoli, G., Pepeu, G. “Oxiracetam and D-Pyroglutamic Acid Antagonize a Disruption of Passive Avoidance Behavior Induced by the N-Methyl-Aspartate Receptor Antagonist 2-amino-5-phosphonovalerate.” Psychopharmacology. 1990, 100, pp. 130-1.
19. Spignoli, G., Magnani, M. Pepeu, G. “Pyroglutamic Acid Antagonizes the Amnesic Effect and the Decrease in Brain Acetylcholine Level Induced by Scopolamine.” Pharmacological Research Communications. 1987, Vol. 10, pp. 901-7.
20. Sabelli HC. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. J Clin Psychiatry 1986;47:66-70.
21. Fischer E et al. Therapy of depression by phenylalanine. Arzneimittelforsch 1975;25:132.
22. Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain. Adv Pain Res Ther 1983;5:305-308.
23. Oberpichler, H, et al. Effects of Ginkgo biloba constituents related to protection against brain damage caused by hypoxia. Pharmacological Research and Communications, 1988; 20:349-368.
24. Oliveira C.S., Piccoli B.C., Aschner M., Rocha J.B.T. Chemical speciation of selenium and mercury as determinant of their neurotoxicity. In: Aschner M., Costa L., editors. Neurotoxicity of Metals. Volume
18. Springer; Cham, Switzerland: 2017. pp. 53–83.
25. Rocha J.B.T., Piccoli B.C., Oliveira C.S. Biological and chemical interest in selenium: A brief historical account. Arkivoc. 2016;2017:457–491. doi: 10.24820/ark.5550190.p009.784. [DOI] [Google Scholar]
26. Rocha J.B.T., Oliveira C.S., Nogara P.A. Toxicology and anticancer activity of synthetic organoselenium compounds. In: Jain V.K., Priyadarsini I., editors. Organoselenium Compounds in Biology and Medicine: Synthesis, Biological and Therapeutic Treatments. Royal Society of Chemistry; London, UK: 2017. pp. 342–376.
27. Nogara P.A., Oliveira C.S., Rocha J.B.T. Chemistry and pharmacology of synthetic organoselenium compounds. In: Ranu B.C., Banerjee B., editors. Organoselenium Chemistry. Wiley; Hoboken, NJ, USA: 2020. pp. 305–346.
28.Nogara P.A., Schimitz G.L., Costa N.S., Kandem J.P., Rocha J.B., Oliveira C.S. The evolution of selenium and mercury research from 1700 to 2017 based on bibliometric analysis. Res. Soc. Dev. 2020;9:e150922177. doi: 10.33448/rsd-v9i2.2177.